Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750324 | 0.86 | ENPP2 (0.45) | ENPP2FABP4TBXA2RPTGDR2HDAC6 | |
| SCHEMBL16750267 | 0.85 | ENPP2 (0.46) | ENPP2CA1CA2PTGDR2HDAC6 | |
| SCHEMBL18044821 | 0.84 | ENPP2 (0.56) | ENPP2CA1CA2FABP4TBXA2R | |
| SCHEMBL18044835 | 0.82 | ENPP2 (0.52) | ENPP2FABP4TBXA2RPTGDRPTGDR2 | |
| SCHEMBL30425869 | 0.82 | ENPP2 (0.52) | ENPP2FABP4TBXA2RPTGDRPTGDR2 | |
| SCHEMBL16742434 | 0.82 | ENPP2 (0.52) | ENPP2FABP4TBXA2RPTGDRPTGDR2 | |
| SCHEMBL16742433 | 0.82 | ENPP2 (0.52) | ENPP2FABP4TBXA2RPTGDRPTGDR2 | |
| SCHEMBL16750207 | 0.81 | ENPP2 (0.43) | ENPP2CA1CA2HDAC6HDAC1 | |
| SCHEMBL18044837 | 0.79 | ENPP2 (0.57) | ENPP2CA1CA2FABP4TBXA2R | |
| SCHEMBL18044836 | 0.79 | ENPP2 (0.57) | ENPP2CA1CA2FABP4TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | DF 2024 IP ACQUISITION, LLC | 2016-09-15 | — | — | US | disclosed |
| WO-2016028686-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | PHARMAKEA, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-9051320-B1 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor | PHARMAKEA, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2015077502-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, UACA | ENPP2 1/4885CA1 1161/4885CA2 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.